### AGENDA ITEM

**Wednesday, October 29th**

<table>
<thead>
<tr>
<th>Time</th>
<th>AGENDA ITEM</th>
<th>PURPOSE</th>
<th>PRESIDER/PRESENTER(s)</th>
</tr>
</thead>
</table>
| 8:00  | Welcome & Introductions           |                  | Dr. Jonathan Temte (ACIP Chair)  
         |                                   |                  | Dr. Larry Pickering (ACIP Executive  
         |                                   |                  | Secretary; CDC)                      |
| 8:30  | Agency Updates                    | Information      | CDC and ex officio members|
| 8:45  | Influenza                         | Information      | CDC and ex officio members|
|       | · Introduction                     |                  | Dr. Ruth Karron (ACIP, WG Chair)  
|       | · Influenza surveillance update    |                  | Dr. Lisa Grohskopf (CDC/NCIRD)    |
|       | · Update on effectiveness of live-attenuated and inactivated seasonal influenza vaccines in children and adolescents | Information & Discussion | Dr. Brendan Flannery (CDC/NCIRD) |
|       | · Administering Afluria® Influenza Vaccine via PharmaJet® Stratis® Needle-Free Injection | Information & Discussion | Dr. Charles Altman (bioCSL) |
| 10:05 | Vaccine Supply                    | Information      | Dr. Jeanne Santoli (CDC/NCIRD) |
| 10:20 | Break                             |                  |                        |
| 10:50 | Novel Influenza                   | Information      | CDC and ex officio members|
|       | · Introduction                     |                  | Dr. Jon Temte (ACIP, WG Member)  
|       | · Influenza A (H5N1) epidemiology and vaccine | Information & Discussion | Dr. Sonja J. Olsen (CDC/NCIRD)    |
|       | · GRADE and policy options for influenza A (H5N1) vaccine | Information & Discussion | Dr. Sonja J. Olsen (CDC/NCIRD)    |
| 11:50 | Pertussis                         | Information      | CDC and ex officio members|
|       | · Introduction                     |                  | Dr. Art Reingold (ACIP, WG Chair)  
|       | · Health-care personnel and Tdap vaccination | Information & Discussion | Dr. Jennifer Liang (CDC/NCIRD)    |
| 12:50 | Lunch                             |                  |                        |
| 2:05  | General Recommendations           | Information      | CDC and ex officio members|
|       | · Introduction                     |                  | Dr. Marietta Vázquez (ACIP, WG Chair)  
|       | · Timing and spacing; contraindications and precautions; vaccine administration | Information & Discussion | Dr. Andrew Kroger (CDC/NCIRD) |
| 3:10  | Child/Adolescent Immunization Schedule | Information      | CDC and ex officio members|
|       | · Introduction                     |                  | Dr. José Romero (ACIP, WG Chair)  
|       | · Child/Adolescent schedule 2015  | Discussion       | Dr. Raymond Strikas (CDC/NCIRD)   |
| 3:55  | Break                             |                  |                        |
| 4:15  | Adult Immunization Schedule       | Information      | CDC and ex officio members|
|       | · Introduction                     |                  | Dr. Laura Riley (ACIP, WG Member)  
|       | · Adult immunization schedule 2015 | Discussion       | Dr. David Kim (CDC/NCIRD)         |
4:45 Hepatitis
· Introduction
· Update on hepatitis A disease burden and hepatitis A population protection

5:30 Public Comment
5:45 Adjourn

Thursday, October 30th
8:00 Unfinished Business

8:15 Meningococcal Vaccines
· Introduction
· 4CMenB serogroup B meningococcal vaccine
· rLP2086 serogroup B meningococcal vaccine
· Epidemiology of serogroup B disease in the United States
· Considerations for use of serogroup B meningococcal vaccines in the US

Public Comment - meningococcal vaccines

10:00 Typhoid Vaccines
· Introduction
· Typhoid vaccines update

10:30 Vaccine Safety
· Proposed changes to the Vaccine Adverse Event Reporting System (VAERS) reporting form

10:45 Break

11:00 Human Papillomavirus (HPV) Vaccines
· Introduction
· Summary and new 9-valent HPV vaccine trial data
· Cost effectiveness Cost effectiveness of 9-valent HPV vaccination
· GRADE for 9-valent HPV vaccine
· Policy options and discussion

1:00 Public Comment
1:15 Adjourn

Acronyms

CDC Centers for Disease Control & Prevention
CMS Centers for Medicare and Medicaid Services
DOD Department of Defense
DVA Department of Veterans Affairs
FDA Food and Drug Administration
GRADE Grading of Recommendations Assessment, Development and Evaluation
HRSA Health Resources and Services Administration
IHS Indian Health Service
NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD CDC National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID National Center for Emerging and Zoonotic Diseases [of CDC/OID]
NIH National Institutes of Health
NVPO National Vaccine Program Office
Tdap Tetanus, Diphtheria, and acellular Pertussis Vaccine
WG Work Group